CN115335058B - 神经细胞变性抑制剂 - Google Patents

神经细胞变性抑制剂 Download PDF

Info

Publication number
CN115335058B
CN115335058B CN202180024013.0A CN202180024013A CN115335058B CN 115335058 B CN115335058 B CN 115335058B CN 202180024013 A CN202180024013 A CN 202180024013A CN 115335058 B CN115335058 B CN 115335058B
Authority
CN
China
Prior art keywords
phenyl
compound
triazin
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180024013.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115335058A (zh
Inventor
井上治久
今村恵子
古泽诚
船田雅昭
林哲
今村圭佑
杉本贵裕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Publication of CN115335058A publication Critical patent/CN115335058A/zh
Application granted granted Critical
Publication of CN115335058B publication Critical patent/CN115335058B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180024013.0A 2020-03-27 2021-03-26 神经细胞变性抑制剂 Active CN115335058B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-058414 2020-03-27
JP2020058414 2020-03-27
PCT/JP2021/014251 WO2021193982A1 (ja) 2020-03-27 2021-03-26 神経細胞変性阻害剤

Publications (2)

Publication Number Publication Date
CN115335058A CN115335058A (zh) 2022-11-11
CN115335058B true CN115335058B (zh) 2024-12-06

Family

ID=77892307

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180024013.0A Active CN115335058B (zh) 2020-03-27 2021-03-26 神经细胞变性抑制剂

Country Status (6)

Country Link
US (1) US20230120205A1 (https=)
EP (1) EP4129293A4 (https=)
JP (1) JP7840054B2 (https=)
CN (1) CN115335058B (https=)
CA (1) CA3172328A1 (https=)
WO (1) WO2021193982A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101247853A (zh) * 2005-04-13 2008-08-20 轴突公司 具有nos抑制活性的取代的吲哚化合物
CN102822150A (zh) * 2010-02-05 2012-12-12 赫普泰雅治疗有限公司 1,2,4-三嗪-4-胺衍生物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
JP5693951B2 (ja) * 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
EP2137164B1 (en) * 2007-04-24 2015-08-26 AstraZeneca AB Inhibitors of protein kinases
EP2137163B1 (en) * 2007-04-24 2015-03-18 AstraZeneca AB Inhibitors of protein kinases
US20130079345A1 (en) * 2010-03-22 2013-03-28 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
TWI555737B (zh) * 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2561867A1 (en) * 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9 inhibitors in the treatment of midline carcinoma
JP6473077B2 (ja) 2013-03-21 2019-02-20 国立大学法人京都大学 神経分化誘導用の多能性幹細胞
CN107530430A (zh) * 2015-01-13 2018-01-02 国立大学法人京都大学 用于预防和/或治疗肌萎缩性侧索硬化症的药剂
CN105085427B (zh) * 2015-08-21 2018-06-05 中国科学院广州生物医药与健康研究院 一类苯并[d]异恶唑类化合物及其应用
GB201605126D0 (en) * 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
CN107304189A (zh) * 2016-04-18 2017-10-31 北京大学 一种三嗪化合物及其制备方法和应用
JP6959632B2 (ja) 2017-05-15 2021-11-02 学校法人近畿大学 筋萎縮性側索硬化症又は前頭側頭型認知症の予防又は治療剤
CN110582491B (zh) * 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
AU2018342105B2 (en) * 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
EP4234553A3 (en) * 2018-05-09 2023-09-06 Design Therapeutics, Inc. Methods and compounds for the treatment of genetic disease
JP7135692B2 (ja) 2018-10-05 2022-09-13 ニプロ株式会社 排液システム

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101247853A (zh) * 2005-04-13 2008-08-20 轴突公司 具有nos抑制活性的取代的吲哚化合物
CN102822150A (zh) * 2010-02-05 2012-12-12 赫普泰雅治疗有限公司 1,2,4-三嗪-4-胺衍生物

Also Published As

Publication number Publication date
US20230120205A1 (en) 2023-04-20
EP4129293A4 (en) 2024-04-03
CN115335058A (zh) 2022-11-11
CA3172328A1 (en) 2021-09-30
EP4129293A1 (en) 2023-02-08
JPWO2021193982A1 (https=) 2021-09-30
JP7840054B2 (ja) 2026-04-03
WO2021193982A1 (ja) 2021-09-30

Similar Documents

Publication Publication Date Title
JP7525903B2 (ja) Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法
AU2015279047B2 (en) Aryl receptor modulators and methods of making and using the same
Wang et al. Dopamine suppresses osteoclast differentiation via cAMP/PKA/CREB pathway
EP1778224B1 (en) Flt3 inhibitors for immune suppression
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
US9839627B2 (en) Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
RS54651B1 (sr) Inhibitori janus kinaza za lečenje suvog oka i drugih očnih obolenja
AU2006286441A1 (en) Benzodiazepines as HCV inhibitors
EP4125910B1 (en) Rho kinase inhibitors for treating frontotemporal dementia
KR20020073176A (ko) 불안증 개선 방법
CN115335058B (zh) 神经细胞变性抑制剂
US20180215705A1 (en) hTRPV1 CHEMICAL AGENTS
JP2013249256A (ja) 脂肪性肝疾患治療薬
HK40082876A (en) Nerve cell degeneration inhibitor
JP2008150371A (ja) 性機能障害を治療するための化合物
WO2015163431A1 (ja) 片頭痛治療剤
CA2907921C (en) Inhibition of il-2 production
EP3875086A1 (en) Dual-inhibitors of cellular necroptosis and ferroptosis for use in the treatment of organ transplant patients
JP7618237B2 (ja) 運動神経細胞変性阻害剤
US20160279079A1 (en) Compositions and methods for treating bone diseases
WO2025254130A1 (ja) 遺伝子発現制御剤
JP2025529834A (ja) 認知障害を処置するためのベンゾアゼピン誘導体、組成物および方法
HK40073574B (zh) 以稠合嘧啶化合物为有效成分的治疗剂
CA3268386A1 (en) TASIPIMIDINE AND CYP2D6 INHIBITOR POLYTHERAPY
RU2667954C2 (ru) Фармацевтическая композиция для лечения функциональных психических расстройств

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant